COVID-19 Vaccine Updates for VFC Providers

Wisconsin Department of Health Services sent this bulletin at 09/11/2025 03:28 PM CDT
Wisconsin Department of Health Services

Wisconsin Vaccines for Children Program (VFC)

COVID-19 Vaccine Updates for VFC Providers

This message is being sent to VFC providers, local health officers, Tribal health directors, local health department staff, local health department nurses and select DHS staff. 

  • The U.S. Food and Drug Administration (FDA) approved updated 2025–26 COVID-19 vaccines for individuals 65 years of age and older and for those 6 months through 64 years old with certain underlying conditions.
  • FDA rescinded Emergency Use Authorizations (EUAs) for certain products. 2024–25 COVID-19 vaccines under an EUA are no longer authorized for use and must be removed from inventory immediately. 
  • At this time COVID-19 vaccines are not available through the VFC or the VFA programs.
  • The Wisconsin Department of Health Services (DHS) acknowledges the uncertainty and potential limitations of COVID-19 vaccine availability due to FDA and ACIP actions. We are actively monitoring federal action on COVID-19 vaccines and are planning for ways to support access to vaccines for Wisconsinites. DHS will communicate additional recommendations and guidance on this topic in the coming weeks.

2024–25 COVID-19 vaccines

The following vaccines are no longer authorized under EUA and must be removed from inventory immediately.  

  • Pfizer-BioNTech COVID-19 Vaccine:
    • 6 months through 4 years (multiple dose vials with yellow caps and labels with yellow borders).
    • 5 years through 11 years (single dose vials with blue caps and labels with blue borders).
  • Moderna COVID-19 Vaccine:
    • 6 months through 11 years (manufacturer-filled syringe (MFS), 0.25mL).
  • Novavax COVID-19 Vaccine:
    • 2 years of age and older (manufacturer-filled syringe, 0.5mL).

Updating inventory in the Wisconsin Immunization Registry (WIR)

To remove unauthorized non-expired COVID-19 doses from your WIR inventory follow the steps below:

  1. Once in your WIR inventory, check the box next to the vaccine lots whose quantities you want to modify.
  2. Select the Modify Quantity button in the upper right corner of your screen
  3. Once redirected to the Modify Quantity screen, select the Action (subtract), enter the number of doses to subtract, select Spoiled as your reason, and select save.
WIR manage inventory

For more detailed instructions you can reference the WIR Inventory Management job aid. 

A return form should then be completed and submitted to vfc@wi.gov to return COVID-19 vaccines that are no longer authorized for use.

For expired doses, no action in WIR is needed as vaccines automatically move to expired inventory.

Approval of 2025–26 COVID-19 vaccines

On August 27, 2025, FDA approved the following 2025–26 COVID-19 vaccine formulations. Privately purchased vaccine is starting to be shipped. At this time the 2025-26 COVID-19 vaccine is not available through the VFC or VFA programs. Availability through these programs is dependent on an ACIP recommendation and resolution to include in the VFC program. The ACIP meeting is currently scheduled for September 18–19, 2025. The immunization program will notify providers if and when COVID vaccine information changes.

Commercially available 2025–26 COVID-19 vaccines

COMIRNATY:

  • 10 mcg formulation for use in individuals 5 years through 11 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
  • 30 mcg formulation for use in individuals who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

SPIKEVAX:

  • 0.25 mL formulation for individuals 6 months through 11 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
  • 0.5 mL formulation for individuals who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

mNEXSPIKE:

  • 0.2 mL formulation for individuals who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
    NUVAXOVID
  • 0.5 mL formulation for individuals who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.